TCRT
Alaunos Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 15 ▼ Alaunos Therapeutics (TCRT) received a delisting notice from Nasdaq…
- Aug 31 ▲ Short interest falls 54.4% to 5.7K
- Sep 18 Offering: Alaunos Therapeutics, Inc. Announces Pricing of Registered…
- Sep 30 ▼ Short interest jumps 60.3% to 9.7K
- Oct 9 ▼ Alaunos Therapeutics received a delisting notice from Nasdaq on Octo…
- Oct 13 ▲ Alaunos Therapeutics (TCRT) has entered into a definitive merger agr…
- Oct 13 ▲ Alaunos Therapeutics completed the acquisition of Velaris Therapeuti…
- Oct 15 Robert W. Postma and WaterMill Asset Management Corp. filed an amend…
- Oct 15 ▼ Short interest jumps 8308.0% to 818.6K
- Oct 21 ▲ Alaunos Therapeutics filed this 8-K to report that, following its Oc…
- Oct 30 ▲ Short interest falls 77.5% to 184.4K
- Nov 13 ▼ Alaunos Therapeutics filed an S-3 shelf registration statement to re…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 1 added (0 new), 2 trimmed or exited.
- Short sellersCOVERING
Short interest −77.5% to 184.4K shares. 1.0 days to cover, ≈4.5% of shares.
- TrendDOWNTREND
3% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 3.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | ADD | $1.1K |
| UBS Group AG | NEAR_EXIT | $60.00 |
| UBS Group AG | TRIM | $2.2K |
| MORGAN STANLEY | ADD | $1.9K |
| ROYAL BANK OF CANADA | DOUBLED | $1.0K |
| WELLS FARGO & COMPANY/MN | DOUBLED | $877.00 |
| UBS Group AG | ADD | $6.5K |
| OSAIC HOLDINGS, INC. | ADD | $5.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Postma Robert W Director Oct 6, 2026 | AWARD | $16.2K |
Weis Holger CEO Oct 6, 2026 | AWARD | $17.5K |
Vieser Jaime Director Oct 6, 2026 | AWARD | $16.9K |
Jerman Michael Allen Director Oct 6, 2026 | AWARD | $15.6K |
Weis Holger CEO Aug 6, 2026 | AWARD | $8.8K |
Vieser Jaime Director Jul 23, 2026 | AWARD | $16.9K |
Weis Holger CEO Jul 23, 2026 | AWARD | $8.8K |
Jerman Michael Allen Director Jul 23, 2026 | AWARD | $15.6K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
Short side
FINRA· Oct 30, 2026| Oct 14, 2026 | Volatility Pause | Resumed |
| Oct 14, 2026 | Volatility Pause | Resumed |
| Oct 13, 2026 | Volatility Pause | Resumed |
| Oct 13, 2026 | Volatility Pause | Resumed |
SecBot reports
11 filings · 3 press releases · 3 bullish · 4 bearish · 4 neutral- BEARISH S-3Nov 12, 2026
Alaunos Therapeutics filed an S-3 shelf registration statement to register 382,090,789 shares of…
Monitor the special meeting for stockholder approval of the conversion and authorized share increase. The massive overhang of 382M registrable shares (vs. 4.2M outstanding) will likely pressure the…
- BULLISH 8-KOct 23, 2026
Alaunos Therapeutics received Nasdaq confirmation that it has regained compliance with the $2.5M…
The delisting risk is resolved for now, but the company still faces ongoing Nasdaq listing requirements and must demonstrate compliance at its next 10-K filing. Monitor the Q4 2026 10-K for…
- BULLISH 8-KOct 21, 2026
Alaunos Therapeutics filed this 8-K to report that, following its October 13, 2026 acquisition of…
The delisting risk is materially resolved by the $350M financing, but Nasdaq has not yet confirmed compliance and will re-evaluate at the next annual report. Monitor for Nasdaq's formal confirmation…
- NEUTRAL SC 13D/AOct 15, 2026
Robert W. Postma and WaterMill Asset Management Corp. filed an amended Schedule 13D disclosing a…
The activist is fully aligned with the merger path, the preferred conversion, voting agreement, and conditional board resignation signal Postma is exiting via the merger rather than escalating…
All TCRT filing & press-release reports (14)
- S-3 reportNov 12, 2026
- 8-K reportOct 23, 2026
- 8-K reportOct 21, 2026
- SC 13D/A reportOct 15, 2026
- SC 13D reportOct 15, 2026
- PRESS-RELEASE reportOct 13, 2026
- 8-K reportOct 13, 2026
- 8-K reportOct 9, 2026
- PRESS-RELEASE reportSep 18, 2026
- 8-K reportSep 16, 2026
- 8-K reportJun 29, 2026
- 8-K reportMay 26, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportMar 2, 2026